Document:

Third Amendment to the Loan and Security Agreement

 Exhibit 10.10 
  
 THIRD AMENDMENT AND WAIVER TO LOAN AND SECURITY AGREEMENT 
 BY AND BETWEEN 
 CONGRESS FINANCIAL CORPORATION (FLORIDA) 
 AND 
 DRUGMAX, INC., TOGETHER WITH ITS
SUBSIDIARIES, 
 VALLEY DRUG COMPANY, VALLEY DRUG COMPANY SOUTH, 
 AND DISCOUNT Rx, INC. 
  
 THIS
THIRD AMENDMENT AND WAIVER TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into effective as of June 30, 2004 (the “Effective Date”), by and among DRUGMAX, INC., a Nevada corporation (“Borrower”), (together
with its subsidiaries, VALLEY DRUG COMPANY, an Ohio corporation, VALLEY DRUG COMPANY SOUTH, a Louisiana corporation, and DISCOUNT Rx, Inc., a Louisiana corporation, also the “Borrower”), and CONGRESS FINANCIAL CORPORATION (FLORIDA), a
Florida corporation (“Lender”). 
  
 W I
T N E S S E T H: 
  
 WHEREAS, Borrower and Lender heretofore entered into that certain Loan and Security Agreement dated effective April 15, 2003 as amended by Amendment No. 1 to Loan and Security Agreement, dated as of August 19, 2003
and Amendment No. 2 to Loan and Security Agreement, dated as of March 31, 2004 (as the same now exists and may hereafter be further amended, modified, supplemented, extended, renewed, restated or replaced, the “Loan Agreement”) pursuant to
which Lender agreed to make loans and provide other financial accommodations to Borrower; and 
  
 WHEREAS, Borrower has requested certain amendments to the Loan Agreement, including with respect to the EBITDA and Tangible Net Worth financial covenants, and a waiver of certain defaults in respect of such covenants,
and Lender is willing to agree to such amendments and waivers, subject to the terms and conditions set forth herein. 
  
 NOW, THEREFORE, for and in consideration of the above premises, the mutual covenants and agreements contained herein and other good and valuable
consideration, the receipt whereof is hereby acknowledged, Borrower and Lender agree as follows: 
  
 1. Definitions. All capitalized terms contained herein shall have the meanings assigned to them in the Loan Agreement unless the context herein
otherwise dictates or unless different meanings are specifically assigned to such terms herein. 

 2. Amendments. The Loan Agreement is hereby amended as follows: 
  
 (a) Section 9.17. Section 9.17 of the Loan Agreement is hereby
amended to read in its entirety as follows: 
  
 “9.17
Tangible Net Worth. Borrower shall maintain Tangible Net Worth of no less than: (i) $470,000 at all times from June 30, 2004 through and including March 30, 2005, (ii) $1,250,000 at all times from March 31, 2005 through and including March
30, 2006, and (iii) $2,000,000 at all times from March 31, 2006 and thereafter.” 
  
 (b) Section 9.18. Section 9.18 of the Loan Agreement is hereby amended to read in its entirety as follows: 
  
 “9.18 EBITDA. Borrower shall not, for any period set forth below (each a “Test Period”), permit its cumulative
EBITDA to be less than the amount set forth opposite such Test Period: 
  

				
	 Test Period

	  	EBITDA

	April 1, 2004 through and including June 30, 2004	  	 	100,000
	July 1, 2004 through and including July 31, 2004	  	 	160,000
	July 1, 2004 through and including August 31, 2004	  	 	325,000
	July 1, 2004 through and including September 30, 2004	  	 	500,000
	July 1, 2004 through and including October 31, 2004	  	 	650,000
	July 1, 2004 through and including November 30, 2004	  	 	825,000
	July 1, 2004 through and including December 31, 2004	  	 	1,000,000
	July 1, 2004 through and including January 31, 2005	  	 	1,150,000
	July 1, 2004 through and including February 28, 2005	  	 	1,300,000
	July 1, 2004 through and including March 31, 2005	  	 	1,500,000
	July 1, 2004 through and including June 30, 2005	  	 	1,800,000
	October 1, 2004 through and including September 30, 2005	  	$	1,800,000
	January 1, 2005 through and including December 31, 2005	  	 	2,000,000
	April 1, 2005 through and including March 31, 2006 and thereafter	  	 	2,000,000

  

 2 

 3. Waiver of Events of Default. 
  
 (a) Subject to the satisfaction of each of the conditions precedent set forth in Section7 hereof, Lender hereby waives the
following Events of Default (collectively, the “Existing Defaults”): 
  
 (i) any Event of Default under Section 10.1(a)(ii) of the Loan Agreement arising as a result of the failure of Borrower to comply with the terms of Section 9.17 of the Loan Agreement as of March 31, 2004, through and
including June 29, 2004; and 
  
 (ii) any Event of Default under
Section 10.1(a)(ii) of the Loan Agreement arising as a result of the failure of Borrower to comply with the terms of Section 9.18 of the Loan Agreement with respect to the consecutive twelve-month period ended March 31, 2004. 
  
 (b) Lender has not waived, is not by this Amendment waiving, and has no
intention of waiving any Event of Default which may have occurred on or prior to the date hereof, whether or not continuing on the date hereof, or which may occur after the date hereof (whether the same or similar to the Events of Default referred
to in Section 3(a) above or otherwise), other than the Existing Defaults (subject to the terms and conditions set forth in Section 3(a) above). The foregoing waiver shall not be construed as a bar to or a waiver of any other or further Event of
Default on any future occasion, whether similar in kind or otherwise and shall not constitute a waiver, express or implied, of any of the rights and remedies of Lender arising under the terms of the Loan Agreement or any other Financing Agreements
on any future occasion or otherwise. 
  
 4. Amendment Fee.
In consideration of the amendments set forth herein, Borrower shall on the date hereof pay to Lender or Lender may, at its option, charge any account of Borrower maintained by Lender, a fee the amount of $25,000, which shall be fully earned as of
the date hereof and shall constitute part of the Obligations, it being understood and agreed that if the transactions contemplated by the Proposal Letter, dated April 5, 2004, between DrugMax, Inc. and Lender (the “Proposal Letter”), shall
have been consummated on or before August 31, 2004, $15,000 of such $25,000 amount specified above shall be credited to a reduction in the amendment fee referred to in Section 5(a) of the Proposal Letter. 
  
 5. Representations, Warranties and Covenants. In addition to the
continuing representations, warranties and covenants heretofore or hereafter made by Borrower to Lender 
  

 3 

 pursuant to the other Financing Agreements, Borrower hereby represents, warrants and covenants with and to Lender as
follows (which representations, warranties and covenants are continuing and shall survive the execution and delivery hereof and shall be incorporated into and made a part of the Financing Agreements): 
  
 (a) The failure of Borrower to comply with the covenants, conditions and
agreements contained herein or in any other agreement, document or instrument at any time executed and/or delivered by Borrower with, to or in favor of Lender shall constitute an Event of Default under the Financing Agreements. 
  
 (b) This Amendment has been duly executed and delivered by Borrower and is in
full force and effect as of the date hereof, and the agreements and obligations of Borrower contained herein constitute legal, valid and binding obligations of Borrower enforceable against Borrower in accordance with their respective terms.

  
 (c) As of the date hereof, no Default or Event of Default has
occurred or is continuing (after giving effect to the amendments and waivers set forth in this Amendment). 
  
 6. Effect of this Amendment. Except as modified pursuant hereto, no other changes, modifications or waivers to or under the Loan Agreement or the
other Financing Agreements are intended or implied and in all other respects the Financing Agreements are hereby specifically ratified and confirmed by the parties hereto as of the effective date hereof. This Amendment represents the entire
agreement and understanding concerning the subject matter hereof between the parties hereto, and supersedes all other prior agreements, understandings, negotiations and discussions, representations, warranties, commitments, proposals, offers and
contracts concerning the subject matter hereof, whether oral or written. To the extent of any conflict between the terms of this Amendment and the other Financing Agreements, the terms of this Amendment shall control. The Loan Agreement and this
Amendment shall be read and construed as one agreement. 
  
 7.
Conditions to Effectiveness of this Amendment. The effectiveness of this Amendment shall be subject to the satisfaction of the following conditions: 
  
 (a) Lender shall have received, in form and substance satisfactory to Lender, an original of this Amendment, duly authorized, executed and delivered by
Borrower; 
  
 (b) Lender shall have received the amendment fee
referred to in Section 3 hereof; and 
  
 (c) Lender shall have
received any and all such further instruments and documents as Lender may require to obtain the full benefits of this Amendment and to protect, preserve and maintain Lender’s rights in the Collateral; 
  
 8. Governing Law. The rights and obligations hereunder of each of the
parties hereto shall be governed by and interpreted and determined in accordance with the laws of the State of Florida without regard to principals of conflicts of laws, but excluding any rule of law that would cause the application of the law of
any jurisdiction other that the laws of the State of Florida. 
  

 4 

 9. Binding Effect. This Amendment shall be binding upon and inure to the benefit of each of the
parties hereto and their respective successors and assigns. 
  
 10. Counterparts. This Amendment may be executed in any number of counterparts, but all of such counterparts shall together constitute but one and the same agreement. In making proof of this Amendment, it shall not be necessary to
produce or account for more than one counterpart thereof signed by each of the parties hereto. This Amendment may be executed and delivered by telecopier with the same force and effect as if it were a manually executed and delivered counterpart.

  
 11. Further Assurances. The parties hereto shall
execute and deliver such additional documents and take such additional action as may be necessary or reasonably desirable to effectuate the provisions and purposes of this Amendment. 
  
 [REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 
  

 5 

 IN WITNESS WHEREOF, Lender and Borrower have caused these presents to be duly executed as of the day and
year first written above. 
  

			
	BORROWER
	
	DRUGMAX, INC.
		
	By:	 	 /s/ Jugal K. Taneja

	Name:	 	Jugal K. Taneja
	Title:	 	Chairman & CEO
	
	VALLEY DRUG COMPANY
		
	By:	 	 /s/ Ronald J. Patrick

	Name:	 	Ronald J. Patrick
	Title:	 	CFO
	
	VALLEY DRUG COMPANY SOUTH
		
	By:	 	 /s/ William LaGamba

	Name:	 	William LaGamba
	Title:	 	COO
	
	DISCOUNT RX, INC.
		
	By:	 	 /s/ William LaGamba

	Name:	 	William LaGamba
	Title:	 	COO
	
	LENDER
	
	CONGRESS FINANCIAL CORPORATION
	(FLORIDA)
		
	By:	 	 /s/ Pat Cloninger

	Name:	 	Pat Cloninger
	Title:	 	Vice PresidentForm of Employees Stock Option Agreement

 Exhibit 10.3 
  
 AMERICAN ACCESS TECHNOLOGIES, INC. 
  
 EMPLOYEE STOCK OPTION AGREEMENT 
  
 American Access Technologies, Inc. (the “Company”), desiring to afford an opportunity to the Grantee named below to purchase
certain shares of the Company’s common stock pursuant to the Company’s 2004 Employee Stock Incentive Plan, hereby grants to Grantee, and the Grantee hereby accepts, an option to purchase the number of such shares optioned as specified
below, during the term ending at midnight (prevailing local time at the Company’s principal offices) on the expiration date of this Option specified below, at the option exercise price specified below, subject to and upon the following terms
and conditions: 
  
 1. Identifying Provisions: As used in this Option, the
following terms shall have the following respective meanings: 
  
 (a) Grantee:
___________________________________________________________________ 
  
 (b) Date
of grant: ___________________________________________________________________ 
  
 (c) Number of shares optioned: ___________________________________________________________________ 
  
 (d) Option exercise price per share: ___________________________________________________________________ 
  
 (e) Expiration date: ___________________________________________________________________ 
  
 This Option is not intended to be and shall not be treated as an incentive stock option under Section 422 of the Internal Revenue Code.

  
 2. Timing of Purchases: Except as otherwise provided herein, this Option may
be exercised until and including the expiration date of this Option whereupon the Option shall expire and may thereafter no longer be exercised. 
  
 3. Restrictions on Exercise: The following additional provisions shall apply to the exercise of this Option: 
  
 (i) Termination of Employment. If the Grantee ceases to be an employee of the Company for any reason other than death only that portion of
this Option exercisable at the time of such termination may thereafter be exercised, and it may not be exercised more than three (3) months after such termination nor after the expiration date of this Option, whichever date is sooner, unless such
termination is by reason of the Grantee’s permanent and total disability, in which case such period of three (3) months shall be extended to one (1) year. 
  

(ii) Death of Grantee. If the Grantee shall die during the term of this Option, the Grantee’s legal representative or representatives, or the person or persons
entitled to do so under the Grantee’s last will and testament or under applicable intestate laws, shall have the right to exercise this Option, but only for the number of shares as to which the Grantee was entitled to exercise this Option in
accordance with Section 2 hereof on the date of his death, and such right shall expire and this Option shall terminate one (1) year after the date of the Grantee’s death or on the expiration date of this Option, whichever date is sooner. In all
other respects, this Option shall terminate upon such death. 
  
 (iii) Approval by
Shareholders. The shareholders of the Company have approved the Plan under which this Option was issued on July 23, 2004. 
  

 (iv) Further Restrictions on Exercise. Exercise of this Option is subject to further restrictions as may be set forth
herein or in an Exhibit hereto. 
  
 4. Non-Transferable: The Grantee may not
transfer this Option except by will or the laws of descent and distribution. This Option shall not be otherwise transferred, assigned, pledged, hypothecated or disposed of in any way, whether by operation of law or otherwise, and shall be
exercisable during the Grantee’s lifetime only by the Grantee or his guardian or legal representative. 
  
 5. Adjustments and Corporate Reorganizations: In the event that the outstanding shares of Common Stock are hereafter changed by reason of recapitalization, reclassification, stock split, combination or exchange of
shares of Common Stock or the like, or by the issuance of dividends payable in shares of Common Stock, an appropriate adjustment shall be made by the Committee, in the number of shares of Common Stock issuable upon exercise of this Option and the
Option Price per share. In the event of any consolidation or merger of the Company with or into another company, or the conveyance of all or substantially all of the assets of the Company to another company, this Option shall upon exercise
thereafter entitle the Grantee to such number of shares of Common Stock or other securities or property to which a holder of shares of Common Stock of the Company would have been entitled to upon such consolidation, merger or conveyance; and in any
such case appropriate adjustment, as determined by the Committee shall be made as set forth above with respect to any future changes in the capitalization of the Company or its successor entity. In the event of the proposed dissolution or
liquidation of the Company, this Option will automatically terminate as of the date of liquidation or termination, unless otherwise provided by the Board of Directors of the Company or any authorized committee thereof. If a fraction of a share of
Common Stock would result from any such adjustment, the adjustment shall be revised to the next higher whole share of Common Stock. 
  
 6. Exercise, Payment For and Delivery of Stock: This Option may be exercised by the Grantee or other person then entitled to exercise it by giving four (4) business
days’ written notice of exercise to the Company specifying the number of shares to be purchased and the total purchase price, accompanied by a check to the order of the Company in payment of such price. If the Company is required to withhold on
account of any present or future tax imposed as a result of such exercise, the notice of exercise shall be accompanied by a check to the order of the Company in payment of the amount of such withholding. Subject to such rules as may be established
by the Committee, the Option Price may also be paid in full by a broker-dealer to whom the Grantee has submitted an exercise notice consisting of a fully endorsed Option, or through any other medium of payment as the Committee, in its discretion,
shall authorize, provided however, no method of payment may be utilized to exercise options by officers and directors of the Company in the event it shall be determined that such method of exercise constitutes a prohibited loan to such person.

  
 7. Alternative Payment with Stock: Notwithstanding the foregoing provisions
requiring payment by check, payment of such purchase price or any portion thereof may be made with shares of stock of the same class as the shares then subject to this Option, if shares of that class are then Publicly Traded (as defined herein),
such shares to be credited toward such purchase price on the valuation basis set forth below, in which event the stock certificates evidencing the shares so to be used shall accompany the notice of exercise and shall be duly endorsed or accompanied
by duly executed stock powers to transfer the same to the Company; provided, however, that such payment in stock instead of cash shall not be effective and shall be rejected by the Company if (i) the Company is then prohibited from purchasing or
acquiring shares of the class of its stock thus tendered to it, or (ii) the right or power of the person exercising the Option to deliver such shares in payment of said purchase price is subject to the prior interests of any other person (excepting
the Company), as indicated by legends upon the certificate(s) or as known to the Company. For credit toward the purchase price, shares so surrendered shall be valued at their Fair Market Value (as defined herein) as of the day immediately preceding
the delivery to the Company of the certificate(s) evidencing such shares. If the Company rejects the payment in stock, the tendered notice of exercise shall not be effective hereunder unless promptly after being notified of such rejection the person
exercising the Option pays the purchase price in acceptable form. If and while payment of the purchase price with stock is permitted in accordance with the foregoing provisions, the person then entitled to exercise this Option may, in lieu of using
previously outstanding shares therefor, use some of the shares as to which this Option is then being exercised, in which case the notice of exercise need not be accompanied by any stock certificates but shall include a statement directing the
Company to withhold so many of the shares that would otherwise have been delivered upon that exercise of this Option as equals the number of shares that would have been transferred to the Company if the purchase price had been paid with previously
issued stock. 
  

 2 

 8. Rights in Shares Before Issuance and Delivery: No person shall be entitled to the privileges of stock ownership in
respect of any shares issuable upon exercise of this Option, unless and until such shares have been issued to such person as fully paid shares. 
  
 9. Requirements of Law and of Stock Exchanges: By accepting this Option, the Grantee represents and agrees for himself and his transferees by will or the laws of descent
and distribution that, unless a registration statement under the Securities Act of 1933 is in effect as to shares purchased upon any exercise of this Option, (i) any and all shares so purchased shall be acquired for his personal account and not with
a view to or for sale in connection with any distribution, and (ii) each notice of the exercise of any portion of this Option shall be accompanied by a representation and warranty in writing, signed by the person entitled to exercise the same, that
the shares are being so acquired in good faith for his personal account and not with view to or for sale in connection with any distribution. 
  
 No certificate or certificates for shares of stock purchased upon exercise of this Option shall be issued and delivered prior to the admission of such shares to listing
on notice of issuance on any stock exchange or other securities market on which shares of that class are then listed, nor unless and until, in the opinion of counsel for the Company, such securities may be issued and delivered without causing the
Company to be in violation of or incur any liability under any federal, state or other securities law, any requirement of any securities exchange listing agreement to which the Company may be a party, or any other requirement of law or of any
regulatory body having jurisdiction over the Company. 
  
 10. Replacement Options.
If and when this Option is exercised and the exercise price is paid with previously outstanding shares or with shares as to which this Option is being exercised, as permitted in paragraph 7 hereof, upon such exercise of this Option the Grantee will
automatically and simultaneously receive a supplemental option (herein sometimes referred to as a “replacement option”) for a number of shares equal to the number of shares delivered by the Grantee in such exercise of this Option, subject
to adjustments of the sort provided in paragraph 5 hereof, at an exercise price per share equal to the Fair Market Value (as defined herein) of the shares subject to the replacement option on the date this Option is thus exercised. Subject to
earlier termination as set forth in Paragraph 3 hereof, the term of the replacement option shall expire and the replacement option shall no longer be exercisable, on the later to occur of (i) the expiration date of the originally exercised Option or
(ii) ten years from the date of grant of the replacement option. The replacement option shall not itself provide for any further replacement options upon its exercise, whether or not the exercise price of the replacement option is paid with
previously outstanding shares or with shares as to which it is being exercised. Notwithstanding anything contained herein to the contrary, no replacement options will be granted hereunder if the Grantee is no longer employed and/or retained by the
Company as of the date of the exercise of this Option. In addition, and notwithstanding anything contained herein to the contrary, in the event there is not a sufficient number of shares of Common Stock authorized for issuance upon exercise of a
replacement option under the Plan, the Company shall use its best efforts to cause such number of authorized shares of Common Stock underlying the Plan to be increased, provided, however, that if the Company is unable to so cause such increase in
the authorized number of shares of Common Stock underlying the Plan to be effectuated, the ability of the Grantee to exercise such replacement option may be delayed indefinitely until such time as the requisite number of shares of Common Stock is so
authorized. 
  
 11. Certain Definitions. As used in this Option: 
  
 “Fair Market Value” of corporate stock shall mean: 
  
 (a) If the stock is then Publicly Traded: The closing price of stock of that class as of the
day in question (or, if such day is not a trading day in the principal securities market or markets for such stock, on the nearest preceding trading day), as reported with respect to the market (or the composite of markets, if more than one) in
which shares of such stock are then traded, or, if no such closing prices are reported, on the basis of the mean between the high bid and low asked prices that day on the principal market or quotation system on which shares of such stock are then
quoted, or, if not so quoted, as furnished by a professional securities dealer making a market in such stock selected by or under authority of the board of directors of the Company. 
  

 3 

 (b) If the stock is then not Publicly Traded: The price at which one could reasonably expect such stock to be sold in an
arm’s length transaction, for cash, other than on an installment basis, to a person not employed by, controlled by, in control of or under common control with the issuer of such shares. Such Fair Market Value shall be that which has currently
or most recently been determined for this purpose by the Company’s board of directors, or at the discretion of that board by an independent appraiser or appraisers selected by the board, in either case giving due consideration to recent
transactions involving shares of such stock, if any, the issuer’s net worth, prospective earning power and dividend-paying capacity, the goodwill of the issuer’s business, the issuer’s industry position and its management, that
industry’s economic outlook, the values of securities of issuers whose stock is Publicly Traded and which are engaged in similar businesses, the effect of transfer restrictions to which such stock may be subject under law and under the
applicable terms of any contract governing such stock, the absence of a public market for such stock and such other matters as the board or its appraiser or appraisers deem pertinent. The determination by the Company’s board of directors or its
appraiser or appraisers of the Fair Market Value shall, if not unreasonable, be conclusive and binding notwithstanding the possibility that other persons might make a different, and also reasonable, determination. If the Fair Market Value to be used
was thus fixed more than sixteen months prior to the day as of which Fair Market Value is being determined, it shall in any event be no less than the book value of the stock being valued at the end of the most recent period for which financial
statements of the issuer are available. 
  
 Corporate stock is “Publicly
Traded” if stock of that class is listed or admitted to unlisted trading privileges on a national securities exchange or on the NASDAQ Stock Market or if sales or bid and offer quotations are reported for that class of stock in the automated
quotation system (“NASDAQ”) operated by the National Association of Securities Dealers, Inc. (“NASD”) or is regularly traded over-the-counter. 
  
 12. Stock Option Plan: This Option is subject to, and the Company and the Grantee agree to be bound by, all of the terms and conditions of
the Company’s 2004 Employee Stock Incentive Plan under which this Option was granted, as the same shall have been amended from time to time in accordance with the terms thereof, provided that no such amendment shall deprive the Grantee, without
his consent, of this Option or any of his rights hereunder. Pursuant to said Plan, the board of directors of the Company or its Committee established for such purposes is vested with final authority to interpret and construe the Plan and this
Option, and is authorized to adopt rules and regulations for carrying out the Plan. A copy of the Plan in its present form is available for inspection during business hours by the Grantee or other persons entitled to exercise this Option at the
Company’s principal office. 
  
 13. Notices: Any notice to be given to the
Company shall be addressed to the Company in care of its Secretary at its principal office, and any notice to be given to the Grantee shall be addressed to him at the address given beneath his signature hereto or at such other address as the Grantee
may hereafter designate in writing to the Company. Any such notice shall be deemed duly given when enclosed in a properly sealed envelope or wrapper addressed as aforesaid, registered or certified, and deposited, postage and registry or
certification fee prepaid, in a post office or branch post office regularly maintained by the United States Postal Service. 
  
 14. Laws Applicable to Construction: This Agreement has been executed and delivered by the Company in Florida, and this Agreement shall be construed and enforced in
accordance with the laws of said State. 
  
 IN WITNESS WHEREOF, the Company has
granted this Option on the date of grant specified above. 
  

									
	 AMERICAN ACCESS TECHNOLOGIES, INC.
	 	 	 	 GRANTEE:
	 	 
				
	 	 	 	 	 ADDRESS:
	 	 
	 By
	 	 	 	 	 	 	 	 
					
	 Title
	 	 	 	 	 	 	 	 

  

 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}]]